- High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer
-
Yazaki S, Kojima Y, Yoshida H, Takamizawa S, Kitadai R, Nishikawa T, Shimoi T, Sudo K, Saito A, Okuma HS, Tanioka M, Noguchi E, Uno M, Ishikawa M, Kato T, Fujiwara Y, Ohe Y, Yonemori K
- KMID: 2537963
- J Gynecol Oncol.
- 2022 Nov;33(6):e82.
- doi: 10.3802/jgo.2022.33.e82
Objective Folate receptor α (FRα) is a membrane protein expressed in various solid tumors but has limited expression in normal cells. Therefore, FRα is an attractive target for cancer treatment. This... -
- CITED
-
- Close
- SHARE
-
- Close
- Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial
-
Fujiwara K, Fujiwara H, Yoshida H, Satoh T, Yonemori K, Nagao S, Matsumoto T, Kobayashi H, Bourgeois H, Harter P, Mosconi AM, Vazquez IP, Reinthaller A, Fujita T, Rowe P, Pujade-Lauraine E, Ray-Coquard I
- KMID: 2526133
- J Gynecol Oncol.
- 2021 Sep;32(5):e82.
- doi: 10.3802/jgo.2021.32.e82
Objective The addition of maintenance olaparib to bevacizumab demonstrated a significant progression-free survival (PFS) benefit in patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1/ENGOT-ov25 trial (NCT02477644). We evaluated maintenance... -
- CITED
-
- Close
- SHARE
-
- Close
